Bliss Biopharma of Hangzhou Licenses Cancer ADC from Morphotek

Morphotek, a US subsidiary of Japan's Eisai, granted Bliss Biopharmaceutical (Hangzhou) exclusive rights to use its eribulin-linker payload to develop a therapeutic antibody drug conjugate against an undisclosed oncology target for the China market. The eribulin-linker payload consists of a cytotoxic agent, eribulin, modified by a chemical linker to facilitate conjugation. The announcement did not disclose specific financial details, but the agreement is comprised of an upfront payment, milestones and sales royalties. BlissBio has an exclusive option to extend the product to the global market and to develop ADCs for two other oncology targets. More details.... Share this with colleagues: // //   Stock Symbol: (TYO: 4523)